New Product Launch: Psyper 2500 by LOST MARY

Innovation by 2FIRSTS.ai
Mar.18.2024
New Product Launch: Psyper 2500 by LOST MARY
South Korean media n.news reported that "LOST MARY" introduced a new product, "Psyper 2500," featuring a detachable design.

Special Note: This article is for industry research and communication purposes only, and does not make any brand or product recommendations; minors are prohibited from accessing.


 

According to South Korean media outlet n.news, "LOST MARY," introduced in Korea for the first time by the Eastern China Commerce Association last year, launched its new product "Psyper 2500" on March 18th.

 

The newly released Psyper 2500 features a detachable design, allowing the disposable pod containing e-liquid to be separated from the device. Users do not need to add additional e-liquid and can easily replace the pod for continued use. The pod has a capacity of 8 milliliters, which, according to the average usage of adult males, can provide up to 2500 puffs. In addition, the device includes a 500mAh battery that can be charged via USB C.

 

The Psyper 2500 offers six flavors, including globally popular options like "Golden Pineapple," "Royal Mango Peach," "Campbell Grape," and "Rainbow Candy," as well as two flavors specifically designed for the Korean market, "Cool Menthol" and "Crown Tobacco." It also comes in six colors, including pink, sapphire, gold, purple, grey, and black.

 

The Psyper 2500 will be available for sale through e-cigarette retailers nationwide starting on the 20th, with a retail price of 10,000 Korean won ($7.50).

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

From Tamarind’s AI Shift to Industry Restructuring, The ‘Amazon Moment’ for Nicotine Is Approaching
From Tamarind’s AI Shift to Industry Restructuring, The ‘Amazon Moment’ for Nicotine Is Approaching
Tamarind Intelligence’s decision to appoint a technology-sector executive as chief executive officer signals more than a leadership reshuffle at a specialist data firm. It reflects a broader structural shift across the global nicotine industry, where companies, regulators and intelligence providers are embedding artificial intelligence into core operations.
Special Report
Feb.18
Fiscal benefit, not health, strongest indicator for vape bans – Contributed by Samrat Chowdhery
Fiscal benefit, not health, strongest indicator for vape bans – Contributed by Samrat Chowdhery
Data shows 75% of nations with state stakes in tobacco trade ban modern substitutes compared to 10% in the free-market group. What is driving these divergent regulations?
Feb.04
Russia’s St. Petersburg Sets Up Working Group to Consider Citywide Vape Sales Ban
Russia’s St. Petersburg Sets Up Working Group to Consider Citywide Vape Sales Ban
Russia’s St. Petersburg legislature has formed a working group to explore tougher controls on vape trade and sales, including the option of a citywide sales ban. The group is set to convene on Jan. 26 with participation from lawmakers, civil society and law enforcement. The move comes as Russia’s federal authorities continue to debate legislation that could allow regions to impose their own restrictions on vapes.
Jan.26 by 2FIRSTS.ai
Exclusive | EU Confirms End of Tobacco Policy Expert Group, Explores New Cooperation Structures as TPD Revision Continues
Exclusive | EU Confirms End of Tobacco Policy Expert Group, Explores New Cooperation Structures as TPD Revision Continues
2Firsts reporting shows that, as the European Union moves toward a future evaluation of its tobacco legislation, the Tobacco Policy Expert Group—long a key platform for coordination among Member States—formally concluded its mandate at the end of 2025. At the same time, the European Commission is exploring new cooperation structures to address the resulting institutional gap.
Jan.22
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
FDA PMTA Roundtable: Ongoing Comprehensive Coverage by 2Firsts
FDA PMTA Roundtable: Ongoing Comprehensive Coverage by 2Firsts
Feb.11